Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Eligibility criteria
Qualifiers
Cohorts 1, 2, and 3: Participants with suspected or confirmed diagnosis of glioblastoma
Cohort 4: Participants with suspected or confirmed diagnosis of vestibular schwannoma
Disqualifiers
Received an investigational drug within 30 days prior to first dose of Panitumumab-IRDye800.
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease as determined by PI; or unstable angina within 6 months prior to enrollment.
History of infusion reactions to monoclonal antibody therapies
Pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- Near-Infrared Fluorescence Imaging
- Panitumumab
- Panitumumab-IRDye800
- POINPOINT-IR9000
Treatment groups
46 Participants
are divided into 4 treatment groupsSponsors and collaborators
Stanford University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov